Selected article for: "air liquid interface and epithelial cell"
Author: Mulay, A.; Konda, B.; Garcia, G.; Yao, C.; Beil, S.; Sen, C.; Purkayastha, A.; Kolls, J. K.; Pociask, D. A.; Pessina, P.; de Aja, J. Sainz; Garcia-de-Alba, C.; Kim, C. F.; Gomperts, B.; Arumugaswami, V.; Stripp, B.R.
Title: SARS-CoV-2 infection of primary human lung epithelium for COVID-19 modeling and drug discovery
  • Cord-id: 3fr1p9gs
  • Document date: 2020_6_29
    • ID: 3fr1p9gs
    Snippet: Coronavirus disease 2019 (COVID-19) is the latest respiratory pandemic resulting from zoonotic transmission of severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2). Severe symptoms include viral pneumonia secondary to infection and inflammation of the lower respiratory tract, in some cases causing death. We developed primary human lung epithelial infection models to understand responses of proximal and distal lung epithelium to SARS-CoV-2 infection. Differentiated air-liquid inte
    Document: Coronavirus disease 2019 (COVID-19) is the latest respiratory pandemic resulting from zoonotic transmission of severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2). Severe symptoms include viral pneumonia secondary to infection and inflammation of the lower respiratory tract, in some cases causing death. We developed primary human lung epithelial infection models to understand responses of proximal and distal lung epithelium to SARS-CoV-2 infection. Differentiated air-liquid interface cultures of proximal airway epithelium and 3D organoid cultures of alveolar epithelium were readily infected by SARS-CoV-2 leading to an epithelial cell-autonomous proinflammatory response. We validated the efficacy of selected candidate COVID-19 drugs confirming that Remdesivir strongly suppressed viral infection/replication. We provide a relevant platform for studying COVID-19 pathobiology and for rapid drug screening against SARS-CoV-2 and future emergent respiratory pathogens.

    Search related documents:
    Co phrase search for related documents
    • acute viral pneumonia and lung alveolar: 1, 2, 3
    • acute viral pneumonia and lung inflammation: 1, 2, 3, 4, 5, 6
    • acute viral pneumonia and lung tissue: 1, 2
    • log reduction and low respiratory: 1
    • log reduction and lung tissue: 1
    • low respiratory and lung alveolar: 1, 2, 3
    • low respiratory and lung inflammation: 1, 2
    • low respiratory and lung tissue: 1, 2, 3, 4, 5, 6, 7
    • low respiratory tract and lung tissue: 1, 2